EGFR and non-small cell lung carcinoma: Recently, the TP53 mutation status has been evaluated as a predictor of the clinical outcome of EGFR‐mutated NSCLC patients undergoing treatment with EGFR‐TKIs.10, 11, 12, 13, 14